Bann‐Mo Day

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

Anne Lynn S. Chang, James Solomon, John D. Hainsworth et al. · Journal of the American Academy of Dermatology · 2013 · 188 citations · Full text

Medicine, Oncology, Pharmacology +8

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic<i>ROS1</i>Fusion–Positive Non–Small-Cell Lung Cancer

Rafał Dziadziuszko, Matthew Krebs, Filippo de Braud et al. · Journal of Clinical Oncology · 2021 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette et al. · The Cancer Journal · 2014 · 52 citations

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials

Anne Lynn S. Chang, Sarah T. Arron, Michael R. Migden et al. · Orphanet Journal of Rare Diseases · 2016 · 35 citations · Full text

Medicine, Dermatology, Oncology +14

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study

Carla Casulo, Bann‐Mo Day, Keith Dawson et al. · Annals of Oncology · 2015 · 30 citations · Full text

Medicine, Oncology, Hematologic Oncology +13